These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2906419)

  • 21. Folate, colitis, dysplasia, and cancer.
    Mason JB
    Nutr Rev; 1989 Oct; 47(10):314-7. PubMed ID: 2574841
    [No Abstract]   [Full Text] [Related]  

  • 22. Megaloblastic anaemia associated with sulphasalazine treatment.
    Schneider RE; Beeley L
    Br Med J; 1977 Jun; 1(6077):1638-9. PubMed ID: 17446
    [No Abstract]   [Full Text] [Related]  

  • 23. 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis.
    Walker AM; Szneke P; Bianchi LA; Field LG; Sutherland LR; Dreyer NA
    Am J Gastroenterol; 1997 May; 92(5):816-20. PubMed ID: 9149192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Influence of salicylazosulphapyridine on folic acid activity in ulcerative rectocolitis (author's transl)].
    Lederer J; Kumps J
    Acta Gastroenterol Belg; 1979; 42(1-2):73-81. PubMed ID: 37686
    [No Abstract]   [Full Text] [Related]  

  • 25. Evaluation of oral administration of folic and folinic acid to prevent folate deficiency in patients with inflammatory bowel disease treated with salicylazosulfapyridine.
    Pironi L; Cornia GL; Ursitti MA; Dallasta MA; Miniero R; Fasano F; Miglioli M; Barbara L
    Int J Clin Pharmacol Res; 1988; 8(2):143-8. PubMed ID: 2897953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study.
    Munk EM; Pedersen L; Floyd A; Nørgård B; Rasmussen HH; Sørensen HT
    Am J Gastroenterol; 2004 May; 99(5):884-8. PubMed ID: 15128355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Folate levels in patients with ulcerative colitis receiving sulphasalazine.
    Schoeman M; Bezuidenhout DJ
    S Afr Med J; 1984 Sep; 66(11):415. PubMed ID: 6148790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sulfasalazine-induced nephrotic syndrome in a patient with ulcerative colitis.
    Molnár T; Farkas K; Nagy F; Iványi B; Wittmann T
    Inflamm Bowel Dis; 2010 Apr; 16(4):552-3. PubMed ID: 19637363
    [No Abstract]   [Full Text] [Related]  

  • 29. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H; Munakata A; Yoshida Y
    J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The treatment of inflammatory bowel disease in children.
    Wyllie R; Sarigol S
    Clin Pediatr (Phila); 1998 Jul; 37(7):421-5. PubMed ID: 9675435
    [No Abstract]   [Full Text] [Related]  

  • 31. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease.
    Korelitz BI; Present DH; Rubin PH; Fochios SE
    J Clin Gastroenterol; 1984 Feb; 6(1):27-31. PubMed ID: 6142067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coombs' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis.
    Mechanick JI
    Mt Sinai J Med; 1985 Oct; 52(8):667-70. PubMed ID: 2867466
    [No Abstract]   [Full Text] [Related]  

  • 33. Drugs and folic acid utilization.
    Nutr Rev; 1971 Feb; 29(2):34-6. PubMed ID: 5098480
    [No Abstract]   [Full Text] [Related]  

  • 34. [A case of depression in the treatment of nonspecific ulcerative colitis with sulfasalazine].
    Rebrov VG; Lukomskiĭ MI
    Klin Med (Mosk); 1989 Aug; 67(8):106. PubMed ID: 2572723
    [No Abstract]   [Full Text] [Related]  

  • 35. [Recurrence-preventive (remission preserving) therapy of chronic inflammatory bowel diseases].
    Kruis W; Pohl C
    Dtsch Med Wochenschr; 1998 Jan; 123(4):85-7. PubMed ID: 9487288
    [No Abstract]   [Full Text] [Related]  

  • 36. Sulfasalazine-induced pericarditis in a patient with ulcerative colitis without recurrence when switching to mesalazine.
    Perrot S; Aslangul E; Szwebel T; Gadhoum H; Romnicianu S; Le Jeunne C
    Int J Colorectal Dis; 2007 Sep; 22(9):1119-21. PubMed ID: 17440739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of sulfasalazine in the treatment of inflammatory bowel disease.
    Spector R
    J Iowa Med Soc; 1983 Jun; 73(6):230-4. PubMed ID: 6135735
    [No Abstract]   [Full Text] [Related]  

  • 38. Folate status in patients receiving maintenance doses of sulfasalazine.
    Longstreth GF; Green R
    Arch Intern Med; 1983 May; 143(5):902-4. PubMed ID: 6148048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Folate deficiency in chronic inflammatory bowel diseases.
    Elsborg L; Larsen L
    Scand J Gastroenterol; 1979; 14(8):1019-24. PubMed ID: 43587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Megaloblastic changes in the cervical epithelium. Association with oral contraceptive therapy and reversal with folic acid.
    Whitehead N; Reyner F; Lindenbaum J
    JAMA; 1973 Dec; 226(12):1421-4. PubMed ID: 4800806
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.